| 18.53 -0.58 (-3.04%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.02  |
1-year : | 27.23 |
| Resists | First : | 21.42 |
Second : | 23.31 |
| Pivot price | 20.77 |
|||
| Supports | First : | 18.36 |
Second : | 15.27 |
| MAs | MA(5) : | 19.51 |
MA(20) : | 20.93 |
| MA(100) : | 18.42  |
MA(250) : | 15.67 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.4 |
D(3) : | 5.5 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 24.59 | Low : | 10.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SI ] has closed above bottom band by 0.8%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.82 - 20.01 | 20.01 - 20.12 |
| Low: | 17.97 - 18.21 | 18.21 - 18.36 |
| Close: | 18.26 - 18.64 | 18.64 - 18.88 |
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Thu, 10 Sep 2026
Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch - PR Newswire
Thu, 10 Sep 2026
About 10% to 15% of people test positive for metal sensitivity. Shoulder Innovations launches an implant. - stocktitan.net
Tue, 08 Sep 2026
Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience - PR Newswire
Tue, 08 Sep 2026
A patent fight over shoulder surgery ends in settlement. Terms remain confidential. - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|